63results about How to "No ethical issues" patented technology

The invention discloses an adipose transplantation material containing highly concentrated adipose-derived stem cells and an extracellular matrix (ECM), and a pure physical preparation method and an application thereof; with application of a fluid vortex principle, most of mature adipocytes in an adipose tissue are broken; at the same time, with application of a flocculation sedimentation technology, oil droplets generated from breaking the adipocytes are gathered and removed. A series of mechanical processing processes are adopted, the pure physical means is adopted, and no any exogenous substances are added. The multiple physical methods are used for removing the mature adipocytes and grease affecting the tissue retention rate after transplantation. In a prepared SVF-gel, the adipose-derived stem cells and endothelial progenitor cells are highly concentrated; the concentrated stromal vascular fraction cells (SVFs) still adhere on the ECM, the number of stem cells fix-planted in local after transplantation is far greater than the ordinary adipose transplantation number; as a stem cell therapy method, the adipose transplantation material has better long-term curative effect.

The invention relates to a method for preparing for organization project cell epimatrix, which adopts animal stromatin and desmocyte as raw material. It comprises: preparing for the culture liquid, extracting the stromatin, preparing for the cell-stromatin culture material, preparing for the cell epimatrix, dispelling the cell by freezing, and sterilization sanitizing packaging material and so on.

The invention discloses a gradient material for guiding regeneration of periodontal hard and soft tissues, and a preparation method of the gradient material. The gradient material is constructed by combining an electrostatic spinning technology with a biological 3D (three dimensional) technology. A micropore structure of an electrostatic spun fibrous membrane can prevent gingival fibroblasts frommigrating to a root surface to play a mechanical barrier role and facilitate transmission of nutrition and metabolism substances; and individualized repair of alveolar bone can be achieved according to clinical requirements since a structure and a shape of a 3D printing scaffold layer are highly designable. The method is simple and stable in preparation technology, and the gradient material integrates a periodontal guided tissue regeneration membrane and an alveolar bone repair scaffold material and has a potency to achieve clinical customized treatment. The gradient material has a good effectof guiding the repair of the hard and soft tissues in vivo and can be better applied to the synchronous regeneration and repair of the alveolar bone and the periodontal tissues.

The invention relates to application and a preparation method of an autologous fibroblast-sourced freeze-dried exosome powder. The autologous fibroblast-sourced freeze-dried exosome powder is appliedinto wrinkle resistance and oxidation resistance, and the application method is as follows: normal saline is used for dissolving the autologous fibroblast-sourced freeze-dried exosome powder into 0.5percent by weight of solvent, so that injection is obtained, and the injection is injected deep into deep stratum of the dermis by a microneedle. The preparation method of the freeze-dried exosome powder comprises four steps, i.e., obtainingment of skin-sourced fibroblasts, cell amplification and cell identification, separation and identification of exosome and freeze-drying of exosome. Since theinvention adopts the autologously sourced exosome to resist wrinkles and oxidation, the autologous fibroblast-sourced freeze-dried exosome powder is easy to store and transport, ethical problems do not exist, moreover, safety is high, and the wrinkle-resistant and oxidation-resistant effect is good.

The invention provides scar removing composition and a dressing comprises a mesenchymal stem cell extract, a fibroblast growth factor and an aloe extract, wherein the mass concentration of the fibroblast growth factor is 10-50 ng/mL, and the mass fraction of the aloe extract is 0.1%-1%; a mesenchymal stem cell culture solution is obtained through sequential culture of P1-P5 generations of mesenchymal stem cells with a mixed culture medium and a phenol-red-free culture medium; the mixed culture medium comprises a DMEM/F12 culture medium and fetal calf serum. The aloe extract is prepared with the following method: epidermis and mesophyll of fresh leaves of aloe vera are separated, then gel juice is squeezed from the mesophyll and sequentially sterilized, concentrated and freeze-dried, and the aloe extract is obtained. The scar removing composition adopts the mesenchymal stem cell culture solution, is low in immunogenicity and harmless to human bodies, is matched with the fibroblast growth factor and the aloe extract and can fade scars and repair skin wound surfaces.

The invention belongs to the technical field of induction and differentiation of stem cells and in particular relates to a medium for inducing differentiation and a method. An induction medium for inducing human adipose tissue-derived stromal cells as nerve cells consists of a solution A, a solution B and a solution C and is prepared by adopting a method comprising the following steps of: preparing the solution A by dissolving 8-12 micrograms of bFGF (Basic Fibroblast Growth Factor) in 500ml of a serum-free medium of the human adipose tissue-derived stromal cells, filtering and degerming to acquire the solution A; preparing the solution B by adding 10-20ml of injection of salviae miltiorrhizae composite into 490-480ml of the serum-free medium of the human adipose tissue-derived stromal cells to acquire the solution B; and preparing the solution C by dissolving 4-8 micrograms of bFGF, 4-8 micrograms of EGF (Epidermal Growth Factor), 40-60 micrograms of BDNF (Brain Derived Neurotrophic Factor) and 80-120 micrograms of GM1 (gangliosides) in 500ml of the serum-free medium of the human adipose tissue-derived stromal cells to acquire the solution C. By adopting the medium for inducing human adipose tissue-derived stromal cells as nerve cells disclosed by the invention, the human adipose tissue-derived stromal cells are differentiated into the nerve cells by adopting the injection of salviae miltiorrhizae composite and combining the growth factors EGF, bFGF, BDNF and GM1; and the induction medium disclosed by the invention is non-toxic in selected induction components, high in induction efficiency and short in induction time; and the exclusion and ethics problems do not exist in the inducted cells after transplanting, so that the induction medium is high in safety.

The process of separating endothelial ancestral cell from human fat tissue relates to method of obtaining seed cell in tissue engineering. Morphological change and cellular immunofluorescene show that the induced cell possesses the phenotype of mature endothelial cell and function of ingesting low density lipoprotein. The detection result with flow cytometer shows that the inducing system possesses very high inducing efficiency. The induced cell forms dendrite bifurcation structure during 3D culture.

The invention relates to the technical field of stem cells and especially relates to a placenta mesenchymal stem cell injection, a preparation method and application thereof. The placenta mesenchymal stem cell injection comprises placenta mesenchymal stem cells, vitamin C, dimethyl sulfoxide (DMSO), fetal calf serum (FBS), human albumin, rhizoma panacis majoris saponin and solvent. The placenta mesenchymal stem cell injection prepared according to the invention is characterized in that the materials are conveniently taken and the ethical violation problem is avoided; the injection prepared according to the invention can effectively preserve the activity of stem cells, can be directly used for recovery, need not be cleaned and centrifuged and is conveniently used; after the injection prepared according to the invention is fed back, the differentiation of the mesenchymal stem cells to the hepatic cells and the maturation of the hepatic cells can be boosted and the GVHD occurrence rate can be reduced.

The invention provides a scar-removing composition which comprises a mesenchymal stem cell culture solution, an epidermal growth factor, vitamin C and vitamin E, wherein the mass concentration of the epidermal growth factor is 10-50ng/mL; the mass concentration of the vitamin C is 5-50mg/mL; the mass concentration of the vitamin E is 5-50mg/m; the mesenchymal stem cell culture solution is prepared by culturing P1-P5 generations of mesenchymal stem cells through a mixture medium and a phenol red-free medium sequentially; and the mixture medium comprises a culture medium DMEM/F12 and fetal calf serum. The scar-removing composition disclosed by the invention adopts the mesenchymal stem cell culture solution, is easy to obtain, low in immunogenicity and harmless to the human body, and the mesenchymal stem cells secrete active materials into the culture solution in the culture process and are matched with the vitamin C, the vitamin E and the epidermal growth factor, so that scars can be effectively reduced, and the skin wound is repaired. The invention also provides a dressing.

The invention belongs to the field of cytobiology, relates to a method for repairing nerve defects in tissue engineering, and in particular relates to a method for repairing artificial peripheral nerve defects by employing schwann cells with a fat source and an application of the method. According to the method, the damaged nerves are repaired by the schwann cells obtained from waste adipose tissues and the nerve defects are repaired by a lot of schwann cells with the fat sources and a few of adipose-derived stem cells in common. An animal experiment proves that regeneration of the damaged nerves can be effectively promoted. The invention provides a novel method for repairing the nerve defects in tissue engineering; a relatively high-quality treatment reference method is provided for repairing of the damaged nerves; and the method provided by the invention has a clinical application prospect and clinical value.

The invention provides a culture medium for separating and inducing human adipose stem cells into pancreatic beta cells and a use method of the culture medium. The optimal culture medium is designed; gene transfection is not required, so that the risk of gene modification and cancers is avoided, few induction steps are used, the use is simple, and the induction time is short and is shortened by 30% in comparison with the prior art; the culture medium is safe, nontoxic and high in success rate of induction. Moreover, after autogenous adipose mesenchymal stem cells are induced and differentiated into insulin-secreting cells, rejection and ethical problems are avoided after autotransplantation, and the safety is high, so that the clinical application prospect is wide. The culture medium is simple, feasible, low in cost and good in use effect.

The invention relates to a use of human amniotic epithelial cells (hAECs) in treatment of autoimmune disease. The invention discloses a method for treating and/or improving the autoimmune disease by using effective dose of the amniotic epithelial cells or cell preparations containing the amniotic epithelial cells alone or in combination with other drugs. The autoimmune disease includes hashimoto thyroiditis, uveitis, lupus erythematosus and the like. The amniotic epithelial cells can be given to patients by local injection or intravenous injection, the dosage range given at each time is about10<3>-10<9> cells, the shortcomings of conventional methods are made up to a certain extent, a good therapeutic effect is generated, and a new clinical treatment scheme is provided for current autoimmune diseases.

The invention relates to application of human amniotic epithelial stem cells in treating acute kidney injury. The invention discloses a method for treating and/or improving acute kidney injury by using an effective dose of human amniotic epithelial stem cells or a cell preparation containing the human amniotic epithelial stem cells independently or in combination with other medicines, and animal experiments adopt an intravenous injection method to give the human amniotic epithelial stem cells to a mouse model. The dose range of each time of administration is 106-107 cells, and the acute kidney injury can be effectively relieved.

The invention discloses a method for inducing human placenta chorionic mesenchymal stem cells to be differentiated into neural stem cells through three-dimensional culture. The method comprises the following steps of mixing three-dimensional materials with a coagel solution; performing coagel treatment for 30 minutes at 37 DEG C; then, adding the human placenta chorionic mesenchymal stem cells; performing culture at 37 DEG C by 5-percent CO<2>; and replacing the culture solution every other day, wherein the coagel solution is a type I collagen solution, a polylactic acid solution or a silk fibroin solution. An in-vivo three-dimensional growth environment is provided for the neural differentiation by using a three-dimensional culture technology; the relation among cells is promoted, so that the cells from multilayer growth; meanwhile, the self updating and multi-directional differentiation features of the stem cells can be better maintained; no chemical inducing factor effect exists, so that the differentiated neural stem cells can be directly used for subsequent clinic tests; and the safety is higher.

A body method of serving as quality stem cell between outside guide marrow to become the smooth muscle cell of blood vessel of the growth factor that joins the source of blood platelet, Is concerned with the method that gets seed cell in organization engineering science. Form studies change and cell immunity fluorescence etc. to prove guide rear cell to have the table type of the smooth muscle cell of blood vessel.

The invention provides a stem cell and a preparation for treating retinosis. Through optimum culture and induced differentiation on mesenchymal stem cells, the efficiency for differentiating the cell into the retina nerve precursor cell is improved; the similar effect to that of the retina precursor cell is achieved in the aspect of the transplantation effect, so that the retina function in the transplantation region is effectively improved; an ideal cell source is provided for the treatment of retinosis diseases through stem cell transplantation; high superiority is realized. A preparation method of the stem cell preparation provided by the invention has the advantages that the preparation process of the stem cell product obtained through separation, culture, posterity pass-down and induction is simple and reliable; the repeatability is good. A use method of the stem cell preparation for treating retinosis provided by the invention belongs to a cell replacing method with the advantages that the operation is simple, the popularization is convenient, and the injury is small. Wide application prospects are realized. The method belongs to the best path for treating the retinosis type degenerative diseases and rescuing the vision.

The invention belongs to the technical field of biological pharmacy, and particularly relates to an application of a pharmaceutical composition containing mesenchymal stem cell to in treatment of diseases. The pharmaceutical composition contains a single-domain antibody and the mesenchymal stem cell exosome, can be used for treating pulmonary fibrosis, can significantly improve a lung tissue system, repair lung tissue damage and reduce inflammatory response, and generates synergistic effects.

The invention provides a method for separating and purifying human amniotic fluid-derived mesenchymal stemcells from discarded supernatant of prenatal diagnosis amniotic fluid culture. The cells are fibroblast-like amniotic fluid-derived mesenchymal stemcells obtained by extremely low-density cultivation in a specific culture medium, have multi-directional differentiation capability, have high amplification capability in comparison with adult cells and can maintain the original characteristics in 15 generations. The method has the main advantages that: (1) raw materials of the method are readily available and have no ethical tissues and an extremely high use value; (2) the cells obtained by using the method have high amplification capability, can maintain the characteristics in 15 generations and have the multi-directional differentiation capability; (3) the cell producing method of the invention is simple and high in efficiency, flow type and magnetic bead separation and purification processes and other separation and purification processes are not required, and the cost for obtaining the high-purity human amniotic fluid-derived mesenchymal stemcells is greatly reduced; and (4) the cells of the invention are applicable to tissue engineering, cell treatment and medicament screening and are suitable to be used as seeded cells of the tissue engineering.

The invention belongs to the technical field of biological pharmacy, and particularly relates to application of a mesenchymal stem cell exosome-containing pharmaceutical composition to treatment of diseases. The pharmaceutical composition comprises a single-domain antibody and mesenchymal stem cell exosomes, and the single-domain antibody and mesenchymal stem cell exosomes can be used for treating pulmonary fibrosis, can significantly improve a lung tissue system, repair lung tissue damage and reduce inflammatory response, and generate a synergistic effect.

The invention relates to the technical field of dental pulp stem and fine treatment, in particular to a method for treating cerebral ischemia reperfusion injury by using a dental pulp stem cell exosome. The method comprises the steps: extraction of exosomes from dental pulp stem cells, extraction of third molars without dental caries and periodontal lesions from healthy volunteers at age of 18 to 30 years-disinfection of tooth surface with 75% alcohol-removal of dental pulp from dental drill-cutting into pieces of 1 mm3-flushing three times with PBS containing 2.5% antibiotic-placement of pulp tissue in 1.5 ml EP tube with digestion of 3 mg/ml type I collagenase-placement in dispase of 4 mg/mL for 30 minutes at 37 DEG C-cell resuspension- and culturing in a 5% CO2 incubator at 37 DEG C; brain tissue is an organ most sensitive to ischemia and hypoxia of the body, irreversible brain injury occurs after blood flow supply is interrupted for several minutes, animal experiments find that the exosome from the dental pulp stem cells can reduce the cerebral infarction area after cerebral ischemia-reperfusion injury of a mouse, and a key technology is provided for clinical application of the dental pulp stem cell exosome in treatment of cerebral ischemia-reperfusion injury.

The invention relates to a method for inducing the differentiation of human amniotic epithelial cells into retinal pigment epithelial cells, and applications thereof in treating retinal degenerative diseases. The method includes adding an inducing composition including 10-100 mM of nicotinamide and 1-10 [mu]M of trichostatin A into human amniotic epithelial cells; and inducing the generated cellsto highly express the typical genes of retinal pigment epithelial cells such as MITF, PMEL17, RPE65 and Bestrophin. Cells induced and generated through the method can be injected into an RCS rat subretinal cavity, the electrophysiological signal of the eyes of a rat can be obviously enhanced through ERG and fundus detection, and fundus structures can be obviously improved, and the thickness of retina can be obviously increased through the displaying of eyeball slice HE staining; the cells induced and differentiated through the above schemes can recover the eyesight of the rat to a certain extent after injection; and the inducing composition can be used for the differentiation of the human amniotic epithelial cells into the retinal pigment epithelial cells and the treatment of retinal damage related eye diseases.

The application belongs to the technical field of stem cell and specifically relates to dressing for treating diabetic foot and a preparation method thereof. The dressing for treating diabetic foot isan effective combination of multiple ingredients such as stem cell growth factors, umbilical cord mesenchymal stem cells, fibroblast and the like. Through compatibility and synergistic interaction ofthe ingredients, wound healing of diabetic foot is promoted. The invention also provides a preparation method of the dressing. Steps are simple to operate, the process is optimized, and large-scale production can be achieved.